Targeting the Rage–Diaph1 Pathway: A Novel Therapeutic Approach for Diabetes Complications Beyond Glucose Control
Bibliographic record
Abstract
Diabetes mellitus remains one of the world’s most challenging chronic diseases, affecting millions and contributing to substantial long-term health complications. Although blood glucose control is a cornerstone of diabetes management, many patients continue to develop vascular damage, impaired wound healing, neuropathy, and inflammation despite maintaining near-normal glycemic levels. This persistent progression of complications highlights the need for therapies that address molecular mechanisms beyond glucose regulation. Recent research has identified the receptor for advanced glycation end-products (RAGE) and its intracellular binding partner DIAPH1 as a major driver of inflammatory and oxidative stress pathways in diabetes. A newly developed small-molecule inhibitor that blocks RAGE–DIAPH1 interaction has shown promising early results in reducing inflammation, improving tissue healing, and mitigating cellular damage independent of glucose levels. This humanized manuscript reviews the biological significance of the RAGE–DIAPH1 axis, summarizes current evidence supporting its therapeutic potential, and evaluates emerging experimental data. While early findings are encouraging, further preclinical validation and human clinical trials are required to establish safety, dosing, and clinical applicability. Targeting the RAGE–DIAPH1 pathway may represent a transformative complementary therapy to protect individuals with diabetes from long-term complications not fully prevented by glucose control.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".